Photo: REMKO DE WAAL
Rebecca discusses how the surge in popularity of Ozempic, a drug heralded for its weight loss properties, has made Novo Nordisk one of Europe’s most valuable companies.
In 2022, US sales of Ozempic contributed to 65% of the firm’s global sales.
And a roundup of the Icehouse Ventures showcase, where New Zealand entrepreneurs pitched their startups to around 900 well-healed potential investors.
Rebecca Stevenson is a senior writer at interest.co.nz
